MannKind Corporation
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving MannKind Corporation now
Current reporting with the operating signal separated from the noise.
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload - Slideshow (NASDAQ:MNKD) 2026-07-31
The story matters when it changes MannKind Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF - Slideshow (NASDAQ:MNKD) 2026-07-30
The story matters when it changes MannKind Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest MNKD filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
MannKind Corporation, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →